+1 (202) 780-3397
Using Protein Array to Search for Clinically Useful Biomarkers
Joint Event on Global Experts Meeting on STD-AIDS and Infectious Diseases & 12th International Conference on Allergy, Immunology and Rheumatology
November 21-22, 2019 | Singapore
Huaizhong Hu
Beijing Konruns Pharmaceutical Co. Ltd, China
Keynote : J Infectious Disease Med Microbiol
Abstract:
Diagnostic biomarkers are required for clinical practice in
situations assessing patient disease status for optimal
management. We used a cytokine/chemokine protein array
to screen for novel biomarkers that were diagnostically
useful. The array consists of over 250 antibody pairs directed
at cytokines/chemokines. Clinical samples of blood, urine
and vaginal fluid were collected and applied on the array for
the screening process. By comparing to the control samples a
panel of candidate proteins were selected from the patients
for further evaluation using quantitative immunoassay.
Based on the quantitative results, the candidates were then
narrowed to 1-3 soluble proteins that were highly sensitive
and specific for the disease diagnosis.
Using the protein array technology we have successfully
identified biomarkers diagnostic for injuries in kidney
transplant, prelabor membrane rupture, and preeclampsia.
These biomarkers are IP-10 and Mig for kidney injury,
sICAM-1 for prelabor membrane rupture, and adipsin for
preeclampsia. These biomarkers are assessed on urine or
vaginal fluid samples, and are highly sensitive and specific
for the disease diagnosis when applied to the patient
management.
Biography:
Huaizhong Hu serves currently as the general manager of the research institute at Beijing Konruns Pharmaceutical Company. Prior to Konruns He spent 10 years at Covance Laboratory and held senior scientific positions. Dr. Hu was a Lee Kuan Yew Research Fellow at the Department of Microbiology, National University of Singapore. He received his Medical Doctor Degree from West China University of Medical Sciences and subsequently his PhD from Utrecht University, The Netherlands. He was a Postdoctoral Fellow in immunology at the NIH where he successfully cloned and functionally evaluated a recombinant immunotoxin that has been developed and tested in a Phase II clinical trial for skin T cell lymphoma. He has authored over 60 publications in peer-reviewed international biomedical journals, and is an inventor of over 30 U.S., Europe and China issued or pending patents.
E-mail: huaizhonghu@yahoo.com
PDF HTML